Hematologic safety of <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

EJNMMI Res · 2021 · PMC8254689 · PMID 34216290

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

In our cohort, a slight trend toward grade ≥ 3 hematologic toxicities, especially thrombocytopenia, was observed with decreasing eGFR values.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.